

Focused Ultrasound Overview

The Technology

Focused ultrasound is an early-stage, noninvasive therapeutic technology with the potential to improve the lives of millions of patients with a variety of serious medical disorders. It offers a disruptive, game changing alternative or complement to surgery, radiation therapy, drug delivery and cancer immunotherapy.

This revolutionary technology has the potential to increase the quality and longevity of life and decrease the cost of care by transforming the treatment of a range of indications including:

- **benign and malignant tumors of the brain, breast, prostate, liver and pancreas**
- **Parkinson's and Alzheimer's disease and epilepsy**
- **depression and obsessive compulsive disorder**
- **arthritis and hypertension**
- **uterine fibroids**

Focused ultrasound treats tissue with multiple intersecting beams of high-frequency sound focused accurately on targets deep in the body without damaging surrounding structures, much like beams of light can be focused on a point with a magnifying glass. At the focal point where the beams converge, the ultrasound energy can act in multiple ways to induce a variety of biological effects enabling the treatment of a wide variety of medical disorders. Currently there are 19 mechanisms of action under study including:

TISSUE DESTRUCTION

- **Thermal Ablation:** coagulative cell death
- **Histotripsy:** mechanical cell disruption
- **Microvascular disruption:** ischemic cell death
- **Sonodynamic therapy:** activation of cell toxic drugs
- **Gene therapy:** activation of apoptotic cell death

DELIVERY OF THERAPEUTIC AGENTS

- **Drugs, genes, growth factors, and stem cells**
- **Increase vascular permeability and blood-brain barrier opening**
- **Increased cell membrane permeability**

IMMUNOMODULATION

- **Tumor cell disruption:** increased immune cell trafficking; exposure of tumor antigens and release of cytokines
- **Augmentation of immunotherapy drugs**
- **Enhanced drug delivery**

RADIATION

- **Alternative to ionizing radiation**
- **Decreased radiation dose:** tumor preconditioning and sensitization


For a complete description of all 19 mechanisms of action, see the Foundation's website www.fusfoundation.org/the-technology/mechanisms-of-action.

There are currently more than 135 clinical indications or disorders in various stages of development, and the number is increasing rapidly. Most are early stage. Worldwide 33 indications have regulatory approval; in the US, six have been approved by the FDA. Focused ultrasound is not for every patient or every disorder. Much work remains to be done to determine where this technology provides unique cost-effective value. For a list of all clinical indications, see the Foundation's website www.fusfoundation.org/diseases-and-conditions-all/overview.

The Problem

It can take decades for a new therapeutic technology like focused ultrasound to become a mainstream standard of care. Every year that is subtracted from that process could reduce death, disability, and suffering for countless people.

Development Status



Development Status



Oncological

Bone metastases
Prostate cancer³
Bone cancer
Breast cancer
Kidney tumors
Liver metastases
Liver tumors
Multiple myeloma²
Pancreatic tumors
Soft tissue cancer
Biliary tract cancer
Brain metastases
Cancer pain
Cervical tumors
Colorectal tumors
Endometrial tumors
Glioblastoma
Head & neck tumors
Lung cancer
Lung metastases
Malignant obstructive jaundice
Melanoma
Multiple tumors¹
Neuroblastoma, pediatric
Ovarian tumors
Pontine glioma
Sacral chordoma
Thyroid cancer
Vaginal tumors
Bladder tumors
Esophageal tumors

Pain

Bone metastases
Arthritis - facetogenic
Bone cancer
Bone tumors, benign
Multiple myeloma²
Neuropathic pain
Osteoid osteoma
Pancreatic tumors
Soft tissue injury
Arthritis
Arthritis - ankle†
Arthritis - hand
Arthritis - hip
Arthritis - knee
Arthritis - sacroiliac
Cancer pain
Dercum's disease†
Desmoid tumors
Painful amputation neuromas
Migraine†
Osteomyelitis†
Rotator cuff injury
Trigeminal neuralgia

Pediatrics

Bone metastases
Osteoid osteoma
Soft tissue cancer
Soft tissue tumor, benign
Astrocytoma (SEGA)
Desmoid tumors
Epilepsy
Multiple tumors¹
Neuroblastoma, pediatric
Sacral chordoma
Arteriovenous malformations
Coarctation of the aorta†
Hydrocephalus
Hypoplastic left heart syndrome
Septal perforation

Desmoid tumor




Uterine fibroid



Pelvic tumor



Pancreatic cancer



The Focused Ultrasound Foundation

SAVING TIME = SAVING LIVES

The Foundation is a unique medical research, education, and advocacy organization created as the catalyst to accelerate the development and adoption of focused ultrasound and thereby reduce death, disability, and suffering for countless patients. To achieve its goals, the Foundation utilizes an approach that is entrepreneurial, high-impact, high performance, market-driven and results oriented.

By identifying opportunities and overcoming barriers, the Foundation is shortening the time from laboratory research to widespread treatment. Major initiatives include:

- Influencing the direction of the field, setting research priorities, and creating an urgent, patient centric culture
- Providing resources, both human and financial capital
- Fostering collaboration and stimulating innovation
- Creating, aggregating and sharing knowledge
- Cultivating the next generation of clinicians and scholars
- Increasing awareness

The Foundation has a robust research program and organizes, conducts, and supports clinical trials and pre-clinical laboratory studies with an emphasis on brain disorders, cancer, and immunotherapy. It is the largest non-governmental source of focused ultrasound research funding.

Board of Directors

Neal F. Kassell, MD

Chairman, Focused Ultrasound Foundation
Former Co-chair of Neurosurgery,
University of Virginia

Scott Beardsley, PhD

Dean, University of Virginia Darden
School of Business

Eugene V. Fife

Founding Principal, Vawter Capital, LLC
Former Chairman, Goldman Sachs
International

John R. Grisham

Author

William A. Hawkins III

Senior Advisor, EW Healthcare Partners
Retired Chairman & CEO, Medtronic

Daniel P. Jordan, PhD

President Emeritus, Thomas Jefferson
Foundation

Syaru Shirley Lin, PhD

Adjunct Faculty, Chinese University of
Hong Kong
Director, Goldman Sachs Asia Bank

Michael R. Lincoln

Global Business Department Chair, Cooley LLP

Michael Milken

Chairman, Milken Institute

Edward D. Miller, MD

Former CEO, Johns Hopkins Medicine

Frederic H. Moll, MD

Chief Development Officer, J&J Medical Devices
Co-founder, Auris Health & Intuitive Surgical

Charles "Wick" Moorman IV

Former Chairman & CEO, Norfolk Southern
Former CEO, Amtrak

Steve H. Rusckowski

Chairman, President and CEO, Quest
Diagnostics Inc.
Former CEO, Philips Healthcare

Gary Shapiro

President & CEO, Consumer Technology
Association (CTA)®

Carl P. Zeithaml, PhD

Former Dean and F. S. Cornell Professor of
Free Enterprise, McIntire School of
Commerce, University of Virginia

Council

Co-chairs

Jane P. Batten

Charles H. Seilheimer, Jr.

.....

John B. Adams, Jr.

Dorothy N. Batten

Ellen Block

Amanda Brown

Deborah Caldwell

Jessica Che-yi Chao

Nancy J. & Thomas N. Chewning

Marguerite & Norwood Davis

Peter Gabriel

David Goode

Rick Hamilton

Diane Heller

Cecelia S. & William J. Howell

Kat Imhoff

Dean L. Kamen

Ann Kingston

Harry Lester

Jonna Mendez

Paula F. Newcomb

Wyndham G. Robertson

Mary Lou Seilheimer

Alice H. Siegel

Allan C. Stam, PhD

Aaron Stern, MD, PhD

Fredi & Howard Stevenson

Bernice Szeto

Andrew C. von Eschenbach, MD

Focused Ultrasound Foundation

For more information, visit www.fusfoundation.org or email FUND@fusfoundation.org

1230 Cedars Court , Suite 206 | Charlottesville, VA 22903 | 434.220.4993